Chronic Lymphocytic Leukemia

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of minimal residual disease (MRD) status in the treatment of patients with chronic lymphocytic leukemia.

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the evolution of therapy in CLL and how physicians are working to balance novel agents with additional modalities.

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy.

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the promise of duvelisib in the treatment landscape of chronic lymphocytic leukemia.

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the impact of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

The FDA has added minimal residual disease data from the phase III MURANO trial to the label for venetoclax for its approved use in combination with rituximab for previously-treated patients with chronic lymphocytic leukemia.

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.